Nellix :: Management Team

Management Team

Robert D. Mitchell, President and Chief Executive Officer
Robert Mitchell became our Chief Executive Officer in March 2008. He has over twenty years of professional experience leading several high technology medical device companies. Prior to joining Nellix, Mr. Mitchell served as Chief Operating Officer & Executive Vice President at AngioDynamics, a NASDAQ-listed public company and leading provider of innovative medical devices to treat cancer and peripheral vascular disease. Mr. Mitchell also served as Director, President and Chief Executive Officer of Millimed Holdings, Inc., a privately held company based in Roskilde, Denmark, developing next-generation drug eluting products centered on the treatment of vascular disease. Much of Mr. Mitchell's professional experience was at Cook Medical Inc., the worlds largest privately held medical device company, where he was responsible for various operations from 1986 to 2003. As Senior Vice President, he led Cook’s largest revenue generating business units including: interventional radiology, cardiology, endovascular, critical care and surgical. Directly following this position, he was employed by NASDAQ-listed Align Technology, Inc. of Santa Clara, California, where he was Vice President of Worldwide Sales and a member of the Executive Management Committee. Mr. Mitchell continues to be actively involved as a lecturer, advisor and board member for several companies, medical societies and humanitarian organizations. Mr. Mitchell received his Bachelor of Science degree from the University of Utah and his MBA from Indiana Wesleyan University.

K.T. Rao, Chief Scientific Officer and Vice President of Research and Development
KT has been involved with the development of emerging medical technologies at Guidant and Johnson & Johnson, and is responsible for all research and development activities at Nellix Endovascular. He led several programs as Director of New Product Development and Pilot Operations at Nitinol Devices & Components and Cordis businesses of J&J, including anastomotic devices to assist beating-heart surgery, intracranial devices to treat wide-necked aneurysms; endovascular stents, filters, guide wires and aortic stent-grafts. Prior to this, at Guidant, as Director of Research in the Stent Business Unit, he directed a robust technology portfolio on stent design, materials, lasers, drug delivery, tissue mechanics and preclinical research, which established and sustained Guidant’s leadership in coronary stents including the introduction of MultiLink Vision, a new cobalt-chromium stent platform. During this time, he was involved with various business development activities related to due diligence, internal ventures and business integration. KT holds BTech, MS and PhD from Indian Institute of Technology at Madras, Purdue and University of California Berkeley, respectively.

Doug Hughes, Chief Financial Officer and Chief Operations Officer
Doug has over 20 years of finance, accounting, investor relations and business development experience in the medical device and consumer products industries. Most recently Doug served as CFO for Evalve, a leader in developing devices for minimally invasive mitral valve repair. Evalve was acquired by Abbott Laboratories in October 2009 and Doug lead the finance transition until June of 2010. Prior to joining Evalve, Doug was CFO for Maquet Cardiovascular and successfully led the transition of this business from Boston Scientific to Maquet. Previously Doug served as Vice President of Finance and Administration for Boston Scientifics’ Cardiac Surgery division and prior to its acquisition, Vice President of Investor Relations for Guidant Corporation. Prior to moving to the medical device industry, Doug worked for The Clorox Company. There he led the finance and accounting operations for the Laundry and Latin America Divisions as well as the Investor Relations Department. Doug received a Master’s of Business Administration from the University of Chicago and a Bachelor’s of Science degree in International Finance from San Francisco State University.